Bipartisan Bill Proposes National Biotechnology Coordination Office to Counter China's Growing Influence
Key Insights
Senators Todd Young (R-IN) and Alex Padilla (D-CA) have introduced the National Biotechnology Initiative Act of 2025, aiming to establish a coordination office under the President to streamline biotech regulations.
The legislation responds to warnings from the National Security Commission on Emerging Biotechnology (search) that China is "dangerously close" to overtaking the U.S. as the global leader in biotechnology innovation.
Industry analysts note the bill could lead to quicker approvals and support manufacturing reshoring efforts, while cautioning that China controls approximately 90% of active pharmaceutical ingredient production globally.
Senators Todd Young (R-IN) and Alex Padilla (D-CA) filed bipartisan legislation Thursday aimed at revitalizing the U.S. biotechnology sector amid growing concerns about China's rapid advancement in the field. The National Biotechnology Initiative Act of 2025 proposes establishing a National Biotechnology Coordination Office (search) (NBCO) under the Office of the President to harmonize federal biotech initiatives and streamline regulatory pathways.
Representatives Stephanie Bice (R-OK) and Ro Khanna (D-CA) introduced a parallel version in the House, demonstrating cross-chamber support for strengthening America's position in biotechnology innovation.
National Security Concerns Drive Legislative Action
The legislation directly responds to warnings from the National Security Commission on Emerging Biotechnology (search) (NSCEB), which recently reported that China is "dangerously close" to overtaking the United States as the global leader in biotechnology innovation. Senator Young, who chairs the NSCEB, along with commissioners Padilla, Bice, and Khanna, are advancing one of the commission's principal recommendations through this bill.
"The U.S. government's approach [in biotech] has been piecemeal and uncoordinated," the NSCEB report stated, highlighting that the country still lacks "high-level departmental and agency leadership we need to execute a national biotechnology strategy."
The proposed NBCO would be led by a director serving as the principal biotechnology advisor to the president, though potential candidates for this position remain unspecified.
Industry Impact and Manufacturing Concerns
Jefferies analysts noted in a communication to investors that the legislation could lead to "quicker approvals" by "optimizing regulatory processes and eliminating unnecessary bureaucracy," which they view as positive for the industry.
The analysts also highlighted that "onshoring manufacturing continues to be a major theme of conversation" across the pharmaceutical sector. Major companies including Eli Lilly, Johnson & Johnson, and Novartis have already announced multibillion-dollar investments in U.S.-based manufacturing facilities, partly in response to potential tariff threats from the incoming Trump administration.
China's Strategic Advantage
China has made biotechnology a clear strategic priority, building capabilities in drug discovery—increasingly powered by artificial intelligence—and biomanufacturing. This focused approach has positioned China to potentially "eclipse" the United States in biotechnology leadership.
A significant concern is China's dominance in pharmaceutical supply chains. According to Jefferies analysts, China controls approximately 90% of active pharmaceutical ingredient (API) production globally. This creates vulnerability for U.S. companies and patients, as China could potentially implement a "retaliatory strategy that does not just utilize tariffs but takes advantage of other strategies such as cutting off API supply."
A May 2024 survey from the Biotechnology Innovation Organization (search) revealed that 79% of U.S. biotech companies have at least one contract with a Chinese contract development and manufacturing organization (CDMO/CMO). Survey respondents indicated they would need up to eight years to completely transition their manufacturing pipelines away from Chinese partners.
Broader Recommendations and Funding Needs
Beyond establishing the NBCO, the NSCEB report outlined approximately 50 recommendations to maintain and expand U.S. leadership in biotechnology. A key recommendation includes a minimum $15 billion investment in the industry over the next five years, with the commission warning that "any smaller amount risks hamstringing U.S. innovation and product development."
Other recommendations focus on creating simpler pathways to market and greater executive action to support research, development, and innovation.
Bipartisan Support with Different Emphases
Jefferies analysts observed "bipartisan support for the Commission," though with slight differences in focus along party lines. Democrats appear more concerned with "limiting damage" from potential tariffs, while Republicans emphasize "maintaining U.S. competitiveness vs China."
As the legislation moves forward, industry observers will be watching for additional bills addressing incentives, supply chain onshoring, investment restrictions, and other issues of concern to investors and biotechnology companies.
The stakes are high, with the NSCEB report suggesting that without sufficient time for companies to adjust their supply chains, "millions of patients could be affected" by disruptions to pharmaceutical manufacturing and availability.